Antares Pharma (Antares Pharma) Interest Expense : $-2.8 Mil (TTM As of Mar. 2022)

View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Antares Pharma's interest expense for the three months ended in Mar. 2022 was $ -0.2 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2022 was $-2.8 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Antares Pharma's Operating Income for the three months ended in Mar. 2022 was $ -2.8 Mil. Antares Pharma's Interest Expense for the three months ended in Mar. 2022 was $ -0.2 Mil. Antares Pharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Antares Pharma Interest Expense Historical Data

The historical data trend for Antares Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Interest Expense Chart

Antares Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Interest Expense

Get a 7-Day Free Trial

-1.42

-2.68

-3.55

-3.79

-3.61

Antares Pharma Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Interest Expense	Get a 7-Day Free Trial															-0.96	-1.14	-0.75	-0.76	-0.17

Antares Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.8 Mil.

Antares Pharma (NAS:ATRS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Antares Pharma's Interest Expense for the three months ended in Mar. 2022 was $-0.2 Mil. Its Operating Income for the three months ended in Mar. 2022 was $-2.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2022 was $23.0 Mil.

Antares Pharma's Interest Coverage for the quarter that ended in Mar. 2022 is calculated as

Antares Pharma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Antares Pharma (Antares Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Princeton South, Suite 300, Ewing, NJ, USA, 08628

Website

https://www.antarespharma.com

Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.

Executives

Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart	director	C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson	officer: See Remarks	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell	officer: Executive Vice President & CFO	C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity	director
Roche Robert P Jr	director	41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob	director	C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham	officer: See Remarks	315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth	director
Robert F Apple	director, officer: President & CEO	C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson	director
Jacques Gonella	director	C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi	officer: EVP, Chief Medical Officer	106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn	officer: VP/Controller & Interim CFO	C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447